Pacific Biosciences of California, Inc. (PACB) Financial Statements
Pacific Biosciences of California, Inc. (PACB) reported trailing twelve-month revenue of $159.3M (up 2.0% year on year) and net income of -$131.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$123.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 655.9M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.03 | 0.03 | 0.03 | 0.06 | 0.09 | 0.09 | 0.09 | 0.08 | 0.09 | 0.08 | 0.13 | 0.13 | 0.20 | 0.15 | 0.16 | 0.16 | |
| Gross profit | 0.01 | 0.00 | 0.01 | 0.02 | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.06 | 0.05 | 0.05 | 0.04 | 0.05 | 0.06 | |
| Research & development | 0.08 | 0.05 | 0.05 | 0.05 | 0.06 | 0.07 | 0.07 | 0.06 | 0.06 | 0.06 | 0.11 | 0.19 | 0.19 | 0.13 | 0.10 | 0.09 | |
| Operating income | — | — | -0.08 | -0.06 | -0.03 | -0.07 | -0.09 | -0.10 | -0.10 | -0.10 | -0.21 | -0.31 | -0.33 | -0.47 | -0.55 | -0.13 | |
| Pre-tax income | — | — | — | — | — | — | — | — | — | — | -0.27 | -0.31 | -0.32 | -0.31 | -0.55 | -0.13 | |
| Income tax | — | — | — | — | — | — | — | — | — | — | -0.09 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | |
| Net income | -0.11 | -0.09 | -0.08 | -0.07 | -0.03 | -0.07 | -0.09 | -0.10 | -0.08 | 0.03 | -0.18 | -0.31 | -0.31 | -0.31 | -0.55 | -0.13 | |
| Diluted EPS ($) | -2.03 | -1.69 | -1.26 | -0.94 | -0.42 | -0.83 | -0.87 | -0.76 | -0.55 | 0.17 | -0.89 | -1.40 | -1.21 | -1.59 | -1.82 | -0.43 | |
| Diluted shares (bn) | — | — | — | — | — | — | — | — | — | 0.175 | 0.204 | 0.225 | 0.254 | 0.288 | 0.300 | — |
USD billions · SEC XBRL
Pacific Biosciences of California, Inc. — questions
- What is Pacific Biosciences of California, Inc.'s revenue?
- $159.3M over the twelve months to 2026-06-30, up 2.0% year on year, from its 10-Q and 10-K filings.
- What is Pacific Biosciences of California, Inc.'s net income?
- -$131.4M over the twelve months to 2026-06-30.
- What is Pacific Biosciences of California, Inc.'s free cash flow?
- -$123.4M over the twelve months to 2026-06-30.
- What are Pacific Biosciences of California, Inc.'s diluted earnings per share?
- $-0.43 over the twelve months to 2026-06-30.
Every figure on this page comes from Pacific Biosciences of California, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.